Akero reported Monday strong results showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused ...
Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...
Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast growth factor 21 analog, designed to treat patients with biopsy-confirmed ...
Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...
After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed ...
Right now, patients with obesity and cirrhosis have few treatments for their progressive liver disease, but a new study ...
Akero's SYMMETRY Phase 2b study showed 50mg EFX achieved 24% cirrhosis reversal in MASH patients, with improvements in liver ...
(ETNB) stock jumped 40% Monday, stoked by positive data for Akero's (AKRO) drug efruxifermin in the treatment of compensated ...
On Monday, at 10:23 a.m. GMT-5, Akero Therapeutics ( AKRO, Financials) saw its stock soar by 106.63%, closing at $54.10, ...
Most ICBs in England do not have effective referral pathways for diagnosing and managing liver disease, an analysis has shown ...
It was the best of biotech times, it was the worst of biotech times: One company soars, another stumbles and a third outlines ...
Cellular senescence, where cells permanently stop dividing, plays a complex role in liver health. In a recent review article, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback